147 related articles for article (PubMed ID: 16832130)
1. Serum tumor markers for pancreatic cancer: the dawn of new era?
Okusaka T; Yamada T; Maekawa M
JOP; 2006 Jul; 7(4):332-6. PubMed ID: 16832130
[No Abstract] [Full Text] [Related]
2. The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancer.
Brody JR; Witkiewicz AK; Yeo CJ
Adv Surg; 2011; 45():301-21. PubMed ID: 21954696
[No Abstract] [Full Text] [Related]
3. [Prognostic significance of CA19-9 levels in patients with pancreatic cancer].
Shiozawa S; Tsuchiya A; Kim DH; Ogawa K
Nihon Rinsho; 2006 Jan; 64 Suppl 1():297-300. PubMed ID: 16457270
[No Abstract] [Full Text] [Related]
4. [Molecular-based treatment concepts in advanced pancreatic cancer].
Boeck S; Moosmann N; Stemmler HJ; Heinemann V
Dtsch Med Wochenschr; 2007 Apr; 132(15):818-22. PubMed ID: 17427093
[No Abstract] [Full Text] [Related]
5. [Chemotherapy for pancreatic cancer].
Kim YT
Korean J Gastroenterol; 2008 Feb; 51(2):111-8. PubMed ID: 18349573
[TBL] [Abstract][Full Text] [Related]
6. CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone.
Wasan HS; Springett GM; Chodkiewicz C; Wong R; Maurel J; Barone C; Rosbrook B; Ricart AD; Kim S; Spano JP
Br J Cancer; 2009 Oct; 101(7):1162-7. PubMed ID: 19724276
[TBL] [Abstract][Full Text] [Related]
7. Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: pretreatment levels or kinetics during chemotherapy?
Boeck S; Schulz C; Stieber P; Holdenrieder S; Weckbach S; Heinemann V
Onkologie; 2007 Feb; 30(1-2):39-42. PubMed ID: 17264524
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib-induced acute hepatitis in a patient with pancreatic cancer.
Saif MW
Clin Adv Hematol Oncol; 2008 Mar; 6(3):191-199. PubMed ID: 18391918
[No Abstract] [Full Text] [Related]
9. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer.
Halm U; Schumann T; Schiefke I; Witzigmann H; Mössner J; Keim V
Br J Cancer; 2000 Mar; 82(5):1013-6. PubMed ID: 10737382
[TBL] [Abstract][Full Text] [Related]
10. Serum cytokine profile in patients with pancreatic cancer.
Torres C; Perales S; Alejandre MJ; Iglesias J; Palomino RJ; Martin M; Caba O; Prados JC; Aránega A; Delgado JR; Irigoyen A; Ortuño FM; Rojas I; Linares A
Pancreas; 2014 Oct; 43(7):1042-9. PubMed ID: 24979617
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinib.
Dediu M; Median D; Alexandru A; Vremes G; Gal C
J BUON; 2007 Sep; 12 Suppl 1():S137-49. PubMed ID: 17935272
[TBL] [Abstract][Full Text] [Related]
12. [Changes in tumor marker levels as a predictor of gemcitabine effect on patients with unresectable or recurrent pancreatic cancer].
Tendo M; Nakata B; Nishino H; Inoue M; Kosaka K; Amano R; Yamada N; Hirakawa K
Gan To Kagaku Ryoho; 2005 Jun; 32(6):795-8. PubMed ID: 15984518
[TBL] [Abstract][Full Text] [Related]
13. Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.
Boeck S; Wittwer C; Heinemann V; Haas M; Kern C; Stieber P; Nagel D; Holdenrieder S
Br J Cancer; 2013 Apr; 108(8):1684-94. PubMed ID: 23579210
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer.
Ikeda M; Okada S; Tokuuye K; Ueno H; Okusaka T
Br J Cancer; 2002 May; 86(10):1551-4. PubMed ID: 12085203
[TBL] [Abstract][Full Text] [Related]
15. CA 19-9 response as an early indicator of the effectiveness of gemcitabine in patients with advanced pancreatic cancer.
Nakai Y; Kawabe T; Isayama H; Sasaki T; Yagioka H; Yashima Y; Kogure H; Arizumi T; Togawa O; Ito Y; Matsubara S; Hirano K; Sasahira N; Tsujino T; Tada M; Omata M
Oncology; 2008; 75(1-2):120-6. PubMed ID: 18784438
[TBL] [Abstract][Full Text] [Related]
16. Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy.
Chiu JW; Wong H; Leung R; Pang R; Cheung TT; Fan ST; Poon R; Yau T
Oncologist; 2014 Sep; 19(9):937-50. PubMed ID: 25117068
[TBL] [Abstract][Full Text] [Related]
17. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.
Ko AH; Hwang J; Venook AP; Abbruzzese JL; Bergsland EK; Tempero MA
Br J Cancer; 2005 Jul; 93(2):195-9. PubMed ID: 15999098
[TBL] [Abstract][Full Text] [Related]
18. Recent updates on the role of chemotherapy in pancreatic cancer.
Burris HA
Semin Oncol; 2005 Aug; 32(4 Suppl 6):S1-3. PubMed ID: 16143160
[TBL] [Abstract][Full Text] [Related]
19. Systemic therapy of advanced pancreatic cancer: has the landscape changed?
Choi M; Razzaque S; Kim R
Clin Adv Hematol Oncol; 2012 Jul; 10(7):442-51. PubMed ID: 22895284
[TBL] [Abstract][Full Text] [Related]
20. Challenges of drug resistance in the management of pancreatic cancer.
Sheikh R; Walsh N; Clynes M; O'Connor R; McDermott R
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1647-61. PubMed ID: 20942635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]